Immunization standards

National regulatory authorities

The assessment, licensure, control, and surveillance of biological medicinal products are major challenges for national regulatory authorities confronted by a steadily increasing number of novel products, complex quality concerns, and new technical issues arising from rapid scientific advances. With the emerging global market the volume of biological medicinal products crossing national borders continues to rise, and it has become critical that regulatory knowledge and experience concerning them can be shared, and approaches to their control harmonized to the greatest extent possible.

Through its consultative approach, WHO identifies and consolidates current consensus opinions on key regulatory issues, and communicates them to national authorities and manufacturers through guidance documents addressing both general issues and specific products. Through this mechanism, national regulatory authorities are informed on the scientific background needed to assess critical issues, and are advised on which regulatory approaches and methodologies have been found to be optimal for insuring the global supply of uniformly high, quality, and efficacious biological medicinal products.

selected examples of guidance documentation to regulalatory authorities:

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



UPCOMING EVENTS


  • WHO working group meeting on RSV vaccine standardization and clinical evaluation, Geneva, Switzerland, 3-5 February 2016
  • TCV workshop, NIBSC, Potters Bar, UK, 8-10 March 2016
  • WHO informal consultation on labelling informatino of influenza vaccines intended to be used for pregnant women, Geneva, Switzerland, 4-5 April 2016
  • WHO information consultation on WHO guidelines on regulatory preparedness for vaccine non-producing countries in response to pandemic influenza emergency, Geneva, Switzerland, 6-7 April 2016
  • WHO working group meeting on guidelines on the quality, safety and efficacy of Ebola vaccines, Geneva, Switzerland, 4-5 May 2016